Literature DB >> 20559200

Emergency department visits involving nonmedical use of selected prescription drugs - United States, 2004-2008.

.   

Abstract

Rates of overdose deaths involving prescription drugs increased rapidly in the United States during 1999-2006. However, such mortality data do not portray the morbidity associated with prescription drug overdoses. Data from emergency department (ED) visits can represent this morbidity and can be accessed more quickly than mortality data. To better understand recent national trends in drug-related morbidity, CDC and the Substance Abuse and Mental Health Services Administration (SAMHSA) reviewed the most recent 5 years of available data (2004-2008) on ED visits involving the nonmedical use of prescription drugs from SAMHSA's Drug Abuse Warning Network (DAWN). This report describes the results of that review, which showed that the estimated number of ED visits for nonmedical use of opioid analgesics increased 111% during 2004-2008 (from 144,600 to 305,900 visits) and increased 29% during 2007-2008. The highest numbers of ED visits were recorded for oxycodone, hydrocodone, and methadone, all of which showed statistically significant increases during the 5-year period. The estimated number of ED visits involving nonmedical use of benzodiazepines increased 89% during 2004-2008 (from 143,500 to 271,700 visits) and 24% during 2007-2008. These findings indicate substantial, increasing morbidity associated with the nonmedical use of prescription drugs in the United States during 2004-2008, despite recent efforts to control the problem. Stronger measures to reduce the diversion of prescription drugs to nonmedical purposes are warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20559200

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  77 in total

1.  Estimates of the population prevalence of injection drug users among hispanic residents of large US metropolitan areas.

Authors:  Enrique R Pouget; Samuel R Friedman; Charles M Cleland; Barbara Tempalski; Hannah L F Cooper
Journal:  J Urban Health       Date:  2012-06       Impact factor: 3.671

2.  Prescription and over-the-counter drug treatment admissions to the California public treatment system.

Authors:  Rachel Gonzales; Mary-Lynn Brecht; Larissa Mooney; Richard A Rawson
Journal:  J Subst Abuse Treat       Date:  2010-12-28

3.  The importance of taking a history of over-the-counter medication use: a brief review and case illustration of "PRN" antihistamine dependence in a hospitalized adolescent.

Authors:  Barbara Gracious; Naomi Abe; Jane Sundberg
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-12       Impact factor: 2.576

4.  Risk factors associated with benzodiazepine use among people who inject drugs in an urban Canadian setting.

Authors:  Devin Tucker; Kanna Hayashi; M-J Milloy; Seonaid Nolan; Huiru Dong; Thomas Kerr; Evan Wood
Journal:  Addict Behav       Date:  2015-10-09       Impact factor: 3.913

5.  Prospective Evaluation of Opioid Consumption Following Carpal Tunnel Release Surgery.

Authors:  Talia Chapman; Nayoung Kim; Mitchell Maltenfort; Asif M Ilyas
Journal:  Hand (N Y)       Date:  2016-04-29

6.  Oxycodone physical dependence and its oral self-administration in C57BL/6J mice.

Authors:  Rachel M Enga; Asti Jackson; M Imad Damaj; Patrick M Beardsley
Journal:  Eur J Pharmacol       Date:  2016-07-05       Impact factor: 4.432

7.  Prescription drug monitoring program inquiry in psychiatric assessment: detection of high rates of opioid prescribing to a dual diagnosis population.

Authors:  Daniel T Hackman; Marion S Greene; Taya J Fernandes; Ashley M Brown; Eric R Wright; R Andrew Chambers
Journal:  J Clin Psychiatry       Date:  2014-07       Impact factor: 4.384

8.  Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.

Authors:  Abby M Bailey; Daniel P Wermeling
Journal:  Ann Pharmacother       Date:  2014-02-12       Impact factor: 3.154

9.  Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.

Authors:  Gail D'Onofrio; Patrick G O'Connor; Michael V Pantalon; Marek C Chawarski; Susan H Busch; Patricia H Owens; Steven L Bernstein; David A Fiellin
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

10.  Medical and nonmedical use of prescription benzodiazepine anxiolytics among U.S. high school seniors.

Authors:  Sean Esteban McCabe; Brady T West
Journal:  Addict Behav       Date:  2014-01-28       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.